Navigation Links
Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Date:2/3/2009

SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the 11th Annual BIO CEO & Investor Conference 2009 on Tuesday, February 10, at 10 a.m. Eastern Time at the Waldorf-Astoria in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration resistant prostate cancers (also known as hormone refractory prostate cancer), as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
2. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
3. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
4. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
5. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
6. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
7. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Poniard Pharmaceuticals Announces Upcoming Conference Participation
9. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... , ... Each year, Crain’s Detroit Business News ranks the most innovative companies ... estate of a company, its impact and significance, and the likelihood of bringing it ... technologies that transform energy sources such as low dose X-ray and convert them into ...
(Date:1/12/2017)... ... January 12, 2017 , ... Huffman Engineering, Inc. , ... who will work in the company’s Lincoln office as a chemical engineer. In ... control systems for customers in the life science manufacturing and water/wastewater industries. , Prior ...
(Date:1/12/2017)... DC , January 12, 2017 ... up the world,s biggest facility for producing mycorrhizae. The ... the nutrient tapping potential of mycorrhizae and developed a ... ... (Logo: http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility ...
(Date:1/12/2017)... Pune, India , January 12, 2017 A new report ... and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the ... million in 2015, growing at a CAGR of 15.07% during the forecast period. ... ... Research Logo ...
Breaking Biology Technology:
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/7/2016)... , December 7, 2016 BioCatch , the ... of its patent portfolio, which grew to over 40 granted and pending ... , , ... filed patent entitled " System, Device, and Method Estimating Force ... enables device makers to forego costly hardware components needed to estimate the ...
Breaking Biology News(10 mins):